Equifax Analysts Cut Their Forecasts After Q1 Results

Equifax Inc. (NYSE:EFX) reported worse-than-expected first-quarter sales results and issued adjusted guidance below estimates on Wednesday. Equifax posted…

Equifax Inc. (NYSE:EFX) reported worse-than-expected first-quarter sales results and issued adjusted guidance below estimates on Wednesday.

Equifax posted quarterly sales of $1.389 billion, missing market estimates of $1.400 billion, according to data from Benzinga Pro.

Equifax said it sees second-quarter adjusted earnings of $1.65 to $1.75 per share, versus market estimates of $1.87 per share. The company expects revenue of $1.41 billion to $1.43 billion, versus expectations of $1.44 billion.

“Equifax performed well in the first quarter against our EFX2026 strategic priorities in a very challenging mortgage market delivering revenue of $1.389 billion, up a strong 7%. Our U.S. mortgage business grew a strong 6% despite a 19% decline in USIS mortgage credit inquiries. Our non-mortgage business, which was about 80% of Equifax revenue in the first quarter, delivered very strong broad-based 9% local currency revenue growth, from continued strong new product performance with a New Product Vitality Index of 9% and 85% of new models and scores built using AI and ML. Workforce Solutions delivered very strong 15% non-mortgage Verification Services revenue growth led by the Government business, with 1% overall growth from the U.S. mortgage market decline,” said Mark W. Begor, Equifax Chief Executive Officer.

Equifax shares fell 8.5% to close at $217.51 on Thursday.

These analysts made changes to their price targets on Equifax following earnings announcement.

  • Baird cut the price target on Equifax from $275 to $260. Baird analyst Jeffrey Meuler maintained an Outperform rating.
  • JP Morgan lowered the price target on Equifax from $290 to $273. JP Morgan analyst Andrew Steinerman maintained an Overweight rating.

Read More: Insiders Buying Lovesac Company And 3 Other Stocks

Total
0
Shares
Related Posts
Read More

Setback For Theseus Pharmaceuticals: Analysts Cut Price Targets But Remain Bullish On Stock

Theseus Pharmaceuticals Inc (NASDAQ: THRX) shares nose-dived after the company announced discontinuing enrollment in the ongoing phase 1/2 study and terminating the development of THE-630 in patients with gastrointestinal stromal tumors (GIST) after reporting 

THRX

Read More

Toyota Faced Major Delays At Mexican Plant Due To Labor Shortages

Toyota Motor Corp (NYSE:TM) has experienced significant production challenges at its Tijuana, Mexico plant, leading to multiple stoppages in February and March. Labor shortages and technical problems caused 19 days of halted production, affecting the Tacoma pick-up truck. This disruption highlights Toyota's vulnerability as it aims to produce 10 million vehicles this year and struggles with labor shortages and supply chain issues.

APIE